Results Provide over 40% Faster Uptake of Insulin
Toronto, Ontario--(Newsfile Corp. - March 3, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") reports its needle-free injection device, InsuJet provides over 40% faster insulin uptake[1] and significantly faster onset of action in diabetic patients compared to needle injections in multiple clinical studies performed in the Netherlands.
Studies were performed at the Radboud University Medical Center in Nijmegen, Netherlands[2],[3] and were published in various influential medical journals including Diabetes Care.
Many patients confirm they notice a faster insulin absorption as evident in the testimonials of many users of InsuJet. Absorption is very beneficial in managing post-meal blood glucose peaks, where conventionally subcutaneously injected insulins still have limitations.
"Data from our past clinical studies, patient testimonials and feedback confirm the benefits of this faster absorption which is bringing many positive benefits to diabetes management. The majority of patients confirm noticeably faster absorption," commented Mr. Nicky Canton, Chief Operation Officer of NuGen. "Time and again we hear that for both children and adults with an active lifestyle that InsuJet, with its needle-free injection delivery, and its quick insulin absorption, has contributed immensely in the management of their diabetes care."
For more information regarding clinical studies, certificates, or InsuJet reports, please visit www.insujet.com and click on the 'Partners' button to learn more. For more information on product testimonials, please visit www.insujet.com and click on the 'Community' button.
"NuGen has become invigorated with a group of like-minded individuals committed to investing time and capital to improve life for millions of diabetics worldwide." Richard Buzbuzian, President & CEO.
About NuGen Medical Devices
NuGen is an emerging specialty medical device company developing the next generation of needle-free technologies and other innovative medical delivery products. The company's products, which include the InsuJet and PetJet needle-free injection systems, are designed to improve the lives of millions of people and animals. NuGen continues to receive approval in numerous countries, including Canada. NuGen's products are designed for use in several important fields including, but not limited to, diabetes, veterinary medicine, and vaccines.
For further information, please visit:
Websites: www.insujet.com and www.nugenmd.com
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/
For further information, please contact:
Tony Di Benedetto
Executive Chairman
(416) 791-9399
tony@nugenmd.com
Richard Buzbuzian
President &CEO
(647) 501-3290
richard@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
[1] de Wit, H.M., Engwerda, E.E.C., Tack, C.J. and de Galan, B.E. (2015), Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. Diabetes Obes Metab, 17: 1093-1099. https://doi.org/10.1111/dom.12550
[2] Elsemiek E.C. Engwerda, Cees J. Tack, Bastiaan E. de Galan; Needle-Free Jet Injection of Rapid-Acting Insulin Improves Early Postprandial Glucose Control in Patients With Diabetes. Diabetes Care 1 November 2013; 36 (11): 3436-3441. https://doi.org/10.2337/dc13-0492
[3] de Wit, H.M. et al. supra note 1.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/157099
